摘要
病理性血管新生是癌症和各种缺血性和炎性疾病的标志,尤其是眼部疾病,如年龄相关性黄斑变性(age-related macular degeneration,AMD)、增生性糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)等。目前抗血管新生的药物治疗主要是针对血管内皮生长因子(vascular endothelial growth factor,VEGF)等促血管生成因子,但是长期局部抑制VEGF或与神经元毒性和一些眼部并发症有关,因此需要寻找其他治疗靶点。内皮细胞代谢在血管新生过程中具有重要调节作用,可独立于VEGF等促血管生成分子的调节过程,有望成为抗血管新生的另一个治疗靶点。目前在一些疾病的血管新生过程中发现了糖酵解的重要调节剂6-磷酸果糖-2-激酶/果糖-2,6-双磷酸酶3(6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3,PFKFB3),本文将介绍PFKFB3的作用,并探讨其作为抗血管新生治疗的内皮细胞代谢靶点的潜力。
Pathological angiogenesis is the mark of cancer and various kinds of ischemic and inflammatory diseases,especially in ocular age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR),etc.Now,the drugs used for inhibiting this pathological angiogenesis are mainly targeted at angiogenic factors such as vascular endothelial growth factor (VEGF),etc.However,there exist damage in neurons and some eye complications after long-term local inhibition of VEGF,which drive us to look for other therapies.Recently,studies have demonstrated that endothelial cell metabolism may also play an important role in regulating angiogenesis in a VEGF-independent way,which makes it another possible new target for antiangiogenic therapy.In angiogenesis of some diseases,the roles of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) was found as the important regulator of glycolysis.This review summarizes the roles of PFKFB3,and discusses its potential as a new antiangiogenic target as well as provide researchers with a clear and innovative thought.
作者
邹蓉
袁源智
ZOU Rong;YUAN Yuan-zhi(Department of Ophthalmology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《复旦学报（医学版）》
CAS
CSCD
北大核心
2019年第5期691-695,共5页
Fudan University Journal of Medical Sciences
基金
国家自然科学基金(81470637,81873680,81600735)~~
